mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.
Saved in:
| Title: | mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models. |
|---|---|
| Authors: | Agrawal N; BioNTech SE, Mainz, Germany., Ates LS; BioNTech SE, Mainz, Germany. louis.ates@biontech.de., Schille SA; BioNTech SE, Mainz, Germany., Chaturvedi A; BioNTech SE, Mainz, Germany., Vogt J; BioNTech SE, Mainz, Germany., Vukovic N; BioNTech SE, Mainz, Germany., Dulberger CL; BioNTech US, Cambridge, MA, USA., Vogel AB; BioNTech SE, Mainz, Germany., Diekmann J; BioNTech SE, Mainz, Germany., Diken M; BioNTech SE, Mainz, Germany. mustafa.diken@biontech.de.; Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz (TRON), Mainz, Germany. mustafa.diken@biontech.de., Şahin U; BioNTech SE, Mainz, Germany.; Helmholtz Institute for Translational Oncology (HI-TRON), Mainz, Germany. |
| Source: | Nature immunology [Nat Immunol] 2026 Jun 12. Date of Electronic Publication: 2026 Jun 12. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1529-2916 |
|---|---|
| DOI: | 10.1038/s41590-026-02545-z |
